BISPECIFIC BINDING MOLECULES THAT TARGET THE TUMOR MICROENVIRONMENT AND AN IMMUNE CHECKPOINT PROTEIN - Patent 3947449

(19)

(11)

EP 3 947 449 A1

(12)

(43)	Date of publication:
	09.02.2022 Bulletin 2022/06

(21)	Application number: 20784051.3

(22)	Date of filing: 31.03.2020

(51)

International Patent Classification (IPC):

C07K 16/24^(2006.01)

C07K 16/28^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	C07K 2317/64; C07K 2317/76; C07K 2319/30; C07K 2317/24; C07K 2317/622; C07K 2319/32; C07K 16/2818; C07K 2317/31

(86)	International application number:
	PCT/US2020/025979

(87)	International publication number:
	WO 2020/205875 (08.10.2020 Gazette 2020/41)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

01.04.2019 US 201962827381 P

(71)	Applicant: Immetas Therapeutics, Inc.
	East Hanover, NJ 07936 (US)

(72)	Inventors:
	WANG, Jin East Hanover, NJ 07936 (US) RAINEY, Godfrey, Jonah East Hanover, NJ 07936 (US)

(74)	Representative: Danner, Stefan
	Danner BioPharm IP Ludwigstraße 8 80539 München 80539 München (DE)

(54)	BISPECIFIC BINDING MOLECULES THAT TARGET THE TUMOR MICROENVIRONMENT AND AN IMMUNE CHECKPOINT PROTEIN